🇺🇸 FDA
Pipeline program

VIR-2482 (450 mg)

VIR-2482-4002

Phase 2 mab terminated

Quick answer

VIR-2482 (450 mg) for Influenza A is a Phase 2 program (mab) at Vir Biotechnology with 1 ClinicalTrials.gov record(s).

Program details

Company
Vir Biotechnology
Indication
Influenza A
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials